USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
HEPATOSYS, INC.
Address:
20521 BETHELWOOD LN
CORNELIUS, NC 28031-7037
Phone:
N/A
URL:
N/A
EIN:
203338398
DUNS:
603868063
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $534,274.00 2
SBIR Phase II $1,397,037.00 1
STTR Phase I $205,508.00 1

Award List:

Perfusion preservation solution for recovery of Donation by Cardiac Death livers

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$172,944.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project is to increase the number of Donation after Cardiac Death (DCD) livers available for transplantation by developing a new hypothermic machine perfusion (HMP) solution for recovery and preservation. Currently DCD livers are… More

Perfusion preservation solution for recovery of Donation by Cardiac Death livers

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,397,037.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project is to increase the number of Donation after Cardiac Death (DCD) livers available for transplantation by developing a new hypothermic machine perfusion (HMP) solution for recovery and p reservation. Currently DCD livers are… More

Human hepatocytes for drug toxicity screening from Cardiac Death Donor livers

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$361,330.00
Agency:
HHS
Principal Investigator:
Mark G. Clemens – 704-687-8682
Abstract:
DESCRIPTION (provided by applicant): Liver toxicity is a major barrier to the FDA approval of many new drugs. Moreover, since the liver is the major site of metabolism of most xenobiotics it is essential to know how the liver metabolizes new drug. Becauseof the many species differences between… More